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Introduction
Dystrophin is an essential component of the oligomeric pro-
tein complex that protects the sarcolemma from the shear-
ing forces of muscle contraction and relaxation. Diminished 
expression and/or production of a faulty dystrophin causes 
the X-linked recessive allelic conditions Duchenne (DMD) and 
Becker muscular dystrophy (BMD). DMD is the most common 
form of childhood muscle wasting, with patients losing ambula-
tion before 12 years of age and, without appropriate health-
care and support, the condition is typically fatal in the second 
decade of life.1 In contrast, BMD presents with more variable 
phenotypes and may display a slower clinical progression, with 
varying levels of impairment2 and in some cases, only minimal 
symptoms such as cramps on exercise and elevation of serum 
creatine kinase.
Consequently, dystrophinopathies can be viewed as a 
spectrum, with DMD, the most severe phenotype being 
caused by the almost or complete failure of the protein. BMD 
typically describes those patients with milder symptoms and 
increased life expectancy resulting from internally deleted 
dystrophin isoforms retaining partial function. The wide range 
of dystrophinopathy phenotypes and the positive correlation 
between dystrophin levels and the age at which indepen-
dent mobility is lost3 suggests that even a modest increase 
in expression of a functional dystrophin isoform could confer 
substantial clinical benefit.
The majority of DMD causing mutations are exon deletions 
that disrupt the reading frame, with two deletion prone regions 
of the gene identified at the 5′ end (minor hotspot) and involving 
exons 45–55 (major hotspot).4 The frame-shifting deletions lead 
to premature translational termination and destabilize the gene 
transcript through the induction of nonsense-mediated decay, 
whereas BMD-causing mutations are typically in-frame dele-
tions that have limited impact on the critical binding domains. 
These observations led to the reading frame rule that correlates 
the genotype/phenotype relationship seen in DMD and BMD.5 
Although more than 90% of mutations described in the dystro-
phin gene abide by this rule, there are exceptions where a pro-
tein-truncating mutation manifests as a mild phenotype, or an 
in-frame deletion has severe consequences (for review see).6 
Some of these exceptions to the reading frame rule can be 
explained by the catastrophic effects of the mutation on crucial 
functional domains, whereas others arise from unanticipated 
consequences to the processing of the dystrophin mRNA. The 
in-frame, genomic deletion of exon 5 has been reported to 
cause DMD, rather than BMD as expected. Subsequent RNA 
studies revealed that the deletion of exon 5 led to the loss of 
exon 6 from the mature mRNA, resulting in a frame-shift that is 
consistent with a DMD phenotype, indicating cross-talk between 
exons during processing.7 Conversely, Ginjaar et al.8 reported 
a nonsense mutation in exon 29 that induced variable levels of 
skipping of this in-frame exon in three boys with DMD, leading to 
mild, moderate, and severe phenotypes within one family.
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Protein-truncating mutations in the dystrophin gene lead to the progressive muscle wasting disorder Duchenne muscular 
dystrophy, whereas in-frame deletions typically manifest as the milder allelic condition, Becker muscular dystrophy. Antisense 
oligomer-induced exon skipping can modify dystrophin gene expression so that a disease-associated dystrophin pre-mRNA is 
processed into a Becker muscular dystrophy-like mature transcript. Despite genomic deletions that may encompass hundreds 
of kilobases of the gene, some dystrophin mutations appear “leaky”, and low levels of high molecular weight, and presumably 
semi-functional, dystrophin are produced. A likely causative mechanism is endogenous exon skipping, and Duchenne 
individuals with higher baseline levels of dystrophin may respond more efficiently to the administration of splice-switching 
antisense oligomers. We optimized excision of exons 8 and 9 in normal human myoblasts, and evaluated several oligomers 
in cells from eight Duchenne muscular dystrophy patients with deletions in a known “leaky” region of the dystrophin gene. 
Inter-patient variation in response to antisense oligomer induced skipping in vitro appeared minimal. We describe oligomers 
targeting exon 8, that unequivocally increase dystrophin above baseline in vitro, and propose that patients with leaky 
mutations are ideally suited for participation in antisense oligomer mediated splice-switching clinical studies.
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Individuals with deletions encompassing exons 3–7 
can  present with clinical severities ranging from BMD to 
DMD,9–11 and several mechanisms have been proposed that 
might moderate the predicted DMD phenotype in these cases; 
restoration of the reading frame by a second mutation, ribo-
somal frame-shifting, the use of alternative promoters, re-ini-
tiation of translation at an in-frame start codon in exon 89,12 
and alternative splicing. We consider the latter possibility most 
likely, as transcripts capable of being translated into a BMD-like 
protein have been detected in dystrophic muscle containing 
another leaky mutation, the deletion of exon 45. Prior et al.13 
identified naturally occurring transcripts missing exons 44 and 
45 that could be translated into a functional dystrophin isoform. 
Induction of functional dystrophin after re-initiation of transla-
tion or the use of alternative promoters from this region of the 
dystrophin gene must be considered highly unlikely, since this 
would eliminate crucial actin binding domains.
Antisense oligomer (AO) mediated exon skipping during 
pre-mRNA processing to restore the reading frame or excise 
exons carrying stop codons is emerging as a promising 
therapy for DMD. This intervention can give rise to a mature 
mRNA that is translated into an internally truncated, but par-
tially functional BMD-like dystrophin isoform. Proof-of-concept 
of this approach was reported after direct intra-muscular injec-
tions of splice-switching oligomers targeting exon 51 to restore 
the reading frame in a subset of DMD deletion patients, using 
either 2′-O-methyl (2OMe) modified bases on a phosphoro-
thioate backbone,14 or a phosphorodiamidate morpholino 
oligomer.15 More recently, dystrophin expression was demon-
strated in muscle after systemic delivery of both oligomers to 
patients with DMD with amenable mutations.16,17
Clinical evaluation of the morpholinooligomer targeting 
exon 51 (AVI-4658, now termed Eteplirsen) revealed that, 
although there were clear differences in dystrophin levels 
before and after oligomer administration, not all participants 
receiving the same dosage responded comparably. With this 
in mind, it is possible that variations in responses to exon 
skipping oligomers will be more pronounced when these 
are applied to mutations that naturally exhibited a degree of 
“leakiness” and result in variable disease severity.
Here we present in vitro data showing that leaky mutations 
in the minor deletion hotspot at the 5′ end of the dystrophin 
gene transcript are highly amenable to AO-induced exon 8 
and 9 skipping, with only modest inter-patient variation. Sev-
eral splice-switching AOs were evaluated, and similar trends 
in exon 8(+9) skipping efficiency by all AOs tested were 
observed in the different patient derived cells. We have previ-
ously shown that directing splice-switching oligomers to exon 
8 resulted in human or canine dystrophin transcripts missing 
both exons 8 and 9.18,19 Indeed, in early canine exon skipping 
studies, RT-PCR carried out using primers targeting exons 
1–9 failed to detect any splice switching, but when amplifica-
tion conditions were modified to include exons 1–10, robust 
exon 8 and 9 skipping was detected.18 Although there appears 
to be cross-talk between dystrophin exons 8 and 9 during 
pre-mRNA processing, this communication appears one way, 
as splice-switching oligomers directed to exon 9 induce spe-
cific removal of the target exon alone. In summary, we have 
designed AOs that induce efficient exon 8 (+9) skipping, and 
propose that these compounds should be considered for 




The splice motif predictor program, exonic splicing enhancer 
(ESE) finder20,21 was used to predict putative ESEs in 
exon 8 (Figure 1a). Using this information, splice-switching 
AOs were designed to induce skipping of exon 8, target-
ing the 3′ acceptor splice site, intra-exonic domains and 
the 5′ donor splice site (Figure 1b), and synthesized as 
2OMe modified bases on a phosphorothioate backbone. 
These AOs were transfected into normal human myoblasts 
as cationic lipoplexes at 100, 200, and 400 nmol/l and sub-
sequent RT-PCR analysis showed most oligomers induced 
pronounced excision of exons 8(+9) (Figure 1c). The loss of 
exon 9 does not disrupt the reading frame and is not consid-
ered contra-indicatory, and AOs targeting the 5′ end of the 
exon (i.e., splice acceptor and ESE motifs) induced the most 
efficient exon excision. These AOs also elicited substantial 
levels of exon 8(+9) skipping in myogenic cells from DMD 
patient 1 (DM1) with a deletion of exons 3–7, as shown in 
Figure 1d. Although, all oligomers induced efficient exon 
skipping at the concentrations tested, H8A(−6+24) appeared 
most effective in that minimal full-length dystrophin transcript 
product was observed. Different primer sets were used to 
amplify this region of the mRNA to minimize size differences 
between amplicons from normal and DMD gene transcripts 
(Table 4).
Evaluation of 2OMe AOs in DMD myoblast (DM) cultures
DMD myoblasts from different patients, three carrying deletions 
of exons 3–7 and one carrying an exon 5–7 deletion were used 
to evaluate the four AOs previously shown to induce robust exon 
8(+9) skipping in normal myogenic cells (Figure 2). Myoblasts 
from two of the patients harboring deletions of dystrophin exons 
3–7, DM1 (Figure 2a) and DM3 (Figure 2b) appeared more 
amenable to induced exon skipping than DM4 patient cells, 
carrying a deletion of dystrophin exons 5–7. DM4 (Figure 2c) 
showed an overall lower response to all AOs but nevertheless 
maintained similar trends, with H8A(−6+24) inducing the most 
efficient exon removal, followed by H8A(+57+83). Pooled data 
from three transfections experiments in DM1, DM3, and DM4 
cells is shown in Figure 2d. Preparations of DM2 patient cells 
were of variable myogenic quality, and generated less consis-
tent data (data not shown).
Evaluation of 2OMe AOs in DMD fibroblast (DF) cultures
The same 2OMe AOs, as cationic lipoplexes (10–400 
nmol/l), were transfected into Ad5.f50.AdApt.MyoD trans-
formed fibroblasts from six unrelated DMD patients with 
deletions of exons 3–7  (Figure 3). In three separate experi-
ments, patient fibroblasts DF2 and DF4 showed inconsis-
tent exon skipping in response to all AOs tested (data not 
shown). DF1 showed a consistently poor but nevertheless 
dose-dependant response to all 2OMe oligomers over the 
range of concentrations tested (Figure 3a). DF3 (Figure 3b), 
DF5 (Figure 3c), and DF6 (Figure 3d), also responded in a 
dose-dependent manner to all AOs tested, with H8A(−6+24) 
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inducing the highest levels of exon 8(+9) skipping. Pooled 
data from four transfections of DF1, DF3, DF5, and DF6 
is shown in Figure 3e. Although the overall level of exon 
skipping  varied, a clear dose-dependant response was evi-
dent and H8A(−6+24) was again one of the most consistent 
splice-switching oligomers.
Evaluation of phosphorodiamidate morpholino  oligomers 
in DMD myogenic cells
Three sequences were selected for synthesis as phospho-
rodiamidate morpholino oligomers (PMOs) and were trans-
fected by nucleofection into myogenic cells from patients 
with DMD (DM1–4), over the concentration range of 10–100 
nmol/l (Figure 4a). Each oligomer induced a dose response 
in each of the myogenic cell strains, with DM1 again showing 
the most consistent response to the oligomers. H8A(−6+24) 
and H8A(−6+18) generated similar levels of exon skipping, 
whereas H8A(+57+83) was consistently less effective than 
the other AOs at all transfection concentrations. Pooled data 
(n = 4) from treatment of DM1–4 is shown in Figure 4b.
Dystrophin expression following PMO conjugated to 
the cell penetrating peptide K transfection
Myogenic cell strains DM1–4 were transfected with oligomers 
H8A(−6+18), H8A(−6+24), and H8A(+57+83), prepared as 
PMO conjugated to the cell penetrating peptide K (PPMOk) 
at a concentration of 2 μmol/l. Seven days after transfection, 
protein and RNA were extracted from the cells for western 
blot and RT-PCR analysis. Extracts from normal myogenic 
cells indicate wild-type levels of protein, and untreated 
patient cells were included to assess base line dystrophin 
arising from “leaky” expression. The western blot membrane 
was probed with NCL-DYS1 and NCL-Hamlet1 to detect 
dystrophin and dysferlin, respectively (Figure 5a). The lat-
ter was included as a high molecular weight, muscle-specific 
loading control. In each of the untreated samples, dystrophin 
was detected, ranging from 3–7% of normal dystrophin levels 
(Figure 5b). Robust dystrophin expression was induced in 
DM1 and DM2 cells, reaching levels of 30–60% of those in 
normal myogenic cells, normalized to dysferlin expression. All 























































































































































Figure 1 Location of exonic splicing enhancers (ESEs) and antisense oligomer (AO) targets in dystrophin exon 8. (a) Locations 
of ESEs in exon 8 and 50 bases of flanking intronic sequence, predicted by ESE finder 3.0.20,21 Predicted splice factor binding sites, and 
relative scores are indicated on the y-axis. Red: SF2/ASF; blue: SC35; green: SRp40; yellow: SRp55. (b) Annealing sites of AOs targeted to 
dystrophin exon 8, relative to positions of predicted splice motifs shown in (a). Evaluation of selected AOs targeted to exon 8 at transfection 
concentrations indicated, in (c) normal human myoblasts and (d) myogenic cells derived from a patient with Duchenne muscular dystrophy 
missing dystrophin exons 3–7. The red bars represent additional oligomers, designed to target the exon 8 acceptor site, that were tested and 
found to induce some exon skipping.
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DM2 showing the greatest increase, from 4% in untreated to 
43–62% in treated cells, representing a 10–14 fold increase 
(Figure 5c). DM1 also showed a marked increase in dys-
trophin levels from 7% in untreated cells, to 31–40% after 
oligomer application. DM3 and DM4 showed more modest 
increases in dystrophin, reaching 17–24% and 12–14% of 
normal dystrophin levels respectively, after oligomer treat-
ment (Figure 5b,c).
RT-PCR analysis showed that in each case, the target 
exons were removed efficiently by all of the oligomers tested, 
with perhaps H8A(+57+83) being marginally less effective as 
indicated by the residual full-length product (Figure 5d,e). 
H8A(−6+18) induced the highest protein levels in DM2 and 
DM3, and resulted inlevels of expression comparable to 
H8A(−6+24) in DM1 and DM4.
Discussion
Exon 51 was selected as the first target for proof-of-concept 
human exon skipping trials,14,15 as this strategy is potentially 
applicable to about 1 in 10 patients with DMD. Depending 
upon the specific database interrogated, the next most com-
mon dystrophin deletion subgroups should respond to skip-
ping of exons 45, 44, or 53 (~1 in 13–20 boys), whereas 
skipping exon 8(+9) would only benefit ~1 in 30 individuals 
with DMD. Another consideration when selecting dystrophin 
deletions that would have the reading frame restored by exon 
51 skipping was that these mutations are considered to be 
absolute, resulting in very low, or undetectable dystrophin. 
This was indeed the case for over half of the participants in 
the Muscular Dystrophy Exon Skipping Consortium trial,15 but 
dystrophin analysis of untreated muscle revealed that several 
boys had 1–2% of normal dystrophin levels, and one had an 
estimated 5% of control levels. In the absence of data from 
pretreatment biopsies, such amounts of dystrophin are likely 
to confound interpretation of the dystrophin induced by tar-
geted exon skipping. However, rigorous dystrophin quantita-
tion in the Morpholino studies,15,16 before and after treatment, 
revealed unequivocal but variable increases in dystrophin 

































































































































































































































Figure 2 Evaluation of 2′-O-methyl (2OMe) antisense oligomers (AOs) targeting dystrophin exon 8 in Duchenne muscular dystrophy 
(DMD) myoblasts. (a–c) RT-PCR analysis of dystrophin transcripts from three DMD myogenic cell strains transfected with the four lead 2OMe 
AOs as lipoplexes, targeted to exon 8 over the concentration range 2.5–400 nmol/l. Gel images show full-length (FL) and induced products 
(refer to Table 4) from (a) DM1 (Δ3–7), (b) DM3 (Δ3–7), and (c) DM4 (Δ5–7). (d) Densitometry data showing relative exons 8 and 9 skipping 
as in (a–c) (n = 3), H8A(−6+18) shown in blue, H8A(−6+24) shown in red, H8A(+42+66) shown in green, and H8A(+57+83) shown in purple 
(mean + SEM).
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participants responded to oligomer treatment by showing 
substantial increases in dystrophin expression (2–18% and 
0.9–17%), whereas a third individual was found to have 7.7% 
dystrophin from a baseline of zero.16
Clinical application of exon 8 skipping should not be 
delayed because of the relatively small proportion of patients 
with DMD who are likely to benefit, but rather, exon 8 should 
be considered a priority, since deletions in this region of the 
dystrophin gene have shown a propensity for inconsistent 
correlation between the genotype and phenotype, and there-
fore may prove highly amenable to exon skipping therapy. 
Since exon 8 (and 9) skipping has been reported to occur 
naturally22,23 this region could be highly amenable to splice 
intervention. Furthermore, the presence of low levels of 
endogenous high molecular weight dystrophin, despite the 
frame-shifting deletions of up to 300 kB, should preclude an 
immune response to the oligomer-induced dystrophin.
Design of AOs to excise exon 8(+9)
The in silico prediction program ESE finder 3.020,21 was used to 
identify domains in dystrophin exon 8 that potentially influence 
pre-mRNA processing. In the first screen, AOs were designed 
to span the acceptor splice site, three intra-exonic domains 
predicted to contain ESEs implicated in exon recognition, 
H8A(+42+66), H8A(+96+120), and H8A(134+158), and the 
donor splice site. 2OMe AOs were used, since we have found 
these oligomers to be excellent as splice-switching research 
tools for AO design. These compounds can be synthesized in-
house and readily transfect cells in vitro as cationic lipoplexes. 
Unlike many other dystrophin exons examined previously, 
where only one or two domains were found to be amenable 
targets for antisense oligomer-induced exon skipping19 exon 8 
was unusual, in that the majority of nonoverlapping oligomers 
evaluated did induce some degree of targeted exon excision, 
indicating the involvement of  several motifs in exon 8 recogni-
tion and inclusion in the mature mRNA.
It is tempting to speculate that the induction of exon 8(+9) 
skipping by several oligomers targeting different motifs may 
correlate to the leakiness of the flanking mutations. Perhaps a 
degree of mis-folding as a result of the deletion in the nascent 
pre-mRNA compromises dystrophin splicing so that exon 
8(+9) is excluded from a proportion of the transcripts. Exclu-
sion of exon 8(+9) from a dystrophin gene transcript missing 
exons 3–7 will restore the reading frame, allowing these tran-
scripts to escape nonsense-mediated decay and accumulate 































































































































































































































Figure 3 Evaluation of 2′-O-methyl (2OMe) antisense oligomers (AOs) targeting dystrophin exon 8 in MyoD transformed Duchenne 
muscular dystrophy (DMD) fibroblasts. (a–d) RT-PCR analysis from unrelated DMD patient fibroblast strains, all carrying a deletion of 
dystrophin exons 3–7, transfected with the four 2OMe AO lipoplexes, targeted to exons 8 at 10–400 nmol/l. Full-length (FL) and oligomer 
induced amplicons are indicated. (e) Densitometry was used to estimate relative exons 8 and 9 skipping induced by H8A(−6+18), shown in 
blue, H8A(−6+24), shown in red, H8A(+42+66), shown in green, and H8A(+57+83), shown in purple (n = 4) (mean + SEM).
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Figure 5 Dystrophin protein expression in PPMOk treated Duchenne muscular dystrophy (DMD) patient myoblasts. (a) Western 
blot showing dystrophin and dysferlin expression in PPMOk transfected (2 μmol/l), untreated (UT) DMD myogenic cells, and untreated 
normal human primary myogenic cells. Full-length dystrophin is 427 kDa, Δ5–9 dystrophin is ~402 kDa and Δ3–9 dystrophin is ~395 kDa. 
Dystrophin and dysferlin (230 kDa) were revealed by NCL-DYS1 and NCL-Hamlet1, respectively using the Western Breeze detection system. 
(b) Densitometry was used to estimate dystrophin expression relative to that in normal human myogenic cells, normalized to dysferlin. 
(c) Densitometry analysis showing relative dystrophin expression, determined by western blotting, as compared with untreated DMD myoblasts 
(fold increase) and normalized to dysferlin expression on the same blot. (d) RT-PCR analysis of exons 8 and 9 skipping levels. Full-length and 
oligomer-induced products are shown. (e) Densitometry analysis showing relative exons 8 and 9 skipping induced by H8A(−6+18) (blue), 








































































































































Figure 4 Evaluation of phosphorodiamidate morpholino oligomers (PMOs), targeting dystrophin exon 8, in Duchenne muscular 
dystrophy (DMD) myoblasts. (a) RT-PCR products from four DMD myoblast strains (DM1 (Δ3–7), DM3 (Δ3–7), and DM4 (Δ5–7) myoblasts) 
transfected with three PMOs using nucleofection. Full-length and oligomer-induced products are shown. (b) Densitometry analysis (n = 4) 
showing relative exons 8 and 9 skipping induced by H8A(−6+18) (blue), H8A(−6+24) (red), H8A(+42+66) (green), and H8A(+57+83) (purple) 
(mean + SEM).
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Using the splice site analyser tool (ibis.tau.ac.il/ssat/SpliceS-
ite), the acceptor and donor splice sites of exons 8 and 9 were 
unremarkable as compared with those of the flanking exons. 
However, dystrophin exon 9 skipping occurs frequently in the 
absence of any oligomer intervention, and has been reported 
to occur in mice, dogs, and humans.24 Exon 9 skipping alone 
was commonly detected in untreated DMD patient cells, and 
although this did not appear to be influenced by oligomers 
directed to exon 8, the propensity for spontaneous exon 9 exci-
sion may contribute to the high levels of dual exon skipping. 
Another feature that distinguishes exon 8 from many other dys-
trophin exons is the length of the preceding intron 7, in excess 
of 110 kb. Intron length does not necessarily reflect ease of 
excision from the mature mRNA, as introns 1 and 2 are in 
excess of 190 and 170 kb, respectively, and exon 2, (62 bp) 
is not efficiently dislodged from the dystrophin mRNA in nor-
mal myogenic cells (K. Greet, S.D. Wilton, unpublished data). 
In contrast, exon 3 (93 bp) was readily removed with oligomers 
targeting ESE motifs near the beginning of the exon, whereas 
targeting the exon 3 donor splice site failed to induce any skip-
ping (unpublished data). Another “leaky” mutation is the deletion 
of exon 45, which is preceded by nearly 250 kb of noncoding 
intervening sequence. These massive introns contain microsat-
ellite repeats, short interspersed elements, long interspresed 
 elements, and transposable elements, and may contribute to 
the relatively high genetic instability of the dystrophin gene.25 
Nevertheless, intron length alone is not the most important 
feature contributing to gene instability within the major deletion 
hotspot, as the small 6.6 kb intron 49 shows a higher density of 
deletion breakpoints than the 37-fold larger intron 44.
We concentrated on targeting splice-switching oligom-
ers to two regions in exon 8, the acceptor splice site and a 
splice enhancer-rich intra-exonic domain in the first-third of 
the exon. Subtle changes in length and oligomer annealing 
site can influence AO efficiency26 hence, additional splice-
switching oligomers were designed to target the annealing 
sites. H8A(−6+18) and H8A(+42+66), and AOs H8A(−6+24) 
and H8A(+57+83) proved to be effective. Although exon skip-
ping was induced by oligomers annealing to the exon 8 donor 
splice site, we did not further pursue this target region. Our 
earlier studies targeting other human dystrophin exons found 
that the acceptor site and beginning of the exon are generally 
the better annealing sites for AO-induced exon excision.19,27
Oligomers H8A(−6+18), H8A(−6+24), H8A(+57+83), and 
H8A(+42+66) were selected for more detailed evaluation as 
2OMe AOs after transfection into DMD patient myoblasts 
and MyoD transformed DMD patient fibroblasts. Again, 
H8A(−6+24) was generally the most effective splice-switch-
ing compound, although the other three oligomers were also 
very effective when evaluated using the 2OMe chemistry.
H8A(−6+18), H8A(−6+24), and H8A(+57+83) were synthe-
sized as PMOs and PPMOk for further evaluation. Interest-
ingly, when evaluated as a PMO in an in vitro titration study, 
H8A(+57+83) was not as efficient at splice switching as 
H8A(−6+18) and H8A(−6+24). However, when compared as 
PPMOks, all three oligomers induced similar levels of exon 
excision and protein production, suggesting a threshold effect 
at the single transfection concentration tested. This empha-
sizes the importance of dose response assays to identify the 
most efficient splice-switching oligomers.
The in vitro data presented here reveal the sequence 
H8A(−6+24) synthesized as the 2OMe AO chemistry as a 
lead candidate sequence for clinical application for amenable 
DMD mutations (e.g., Δ3–7, Δ4–7, Δ5–7, and Δ6–7). Although 
2OMe AOs are chemically modified and have greater nucle-
ase resistance than naturally occurring nucleic acids, degra-
dation does occur. It could be surmised that although shorter 
2OMe AO sequences (e.g., H8A(−6+18)) do induce splice 
switching, the longer the original oligomer (H8A(−6+24)), the 
more effective the degradation products. Differences in splice-
switching efficiencies between H8A(−6+18) and H8A(−6+24) 
were less obvious when these sequences were evaluated 
as the more stable PMOs. In addition, the extra 6 bases in 
H8A(−6+24) do not appear to increase the potential for off-
target effects, as both target sequences produced a single 
potential hit with 50 and 68% coverage, respectively, when 
submitted to a BLAST search of human genomic and tran-
script sequences (data not shown). However, if PMO oligomer 
production costs are considered, the shorter H8A(−6+18) 
may be more cost effective for clinical application.
Although shorter oligomers are more economical to produce 
and have less potential for cross-annealing to homologous 
sequences, it would be counter productive to use the shorter 
“inexpensive” oligomers if they are significantly less effective as 
splice switching agents. For example, H8A(−6+14), when trans-
fected into normal cells as a 2OMe AO, induced only minimal 
exon skipping at concentrations of 300 nmol/l or above (data 
not shown). Nevertheless, it is sometimes difficult to distinguish 
relative skipping efficiencies of suboptimal compounds trans-
fected into patient DMD cells, unless tested at low concentra-
tions to allow discrimination of the more potent compounds. 
Exclusion of dystrophin exons 8 and 9 in cells from a patient 
missing exons 3–7, generates in-frame transcripts that escape 
nonsense-mediated decay, and the induced transcript would 
therefore have a longer half-life than the out-of-frame transcript. 
This could lead to overestimation of exon skipping efficiency, 
and hence, it is important to evaluate AOs in both normal and 
patient cells, and over a range of transfection concentrations.
Although myogenic cells from the patients with DMD are 
greatly preferred for oligomer evaluation in vitro, there are 
limitations to using muscle-derived cells from the patients 
with DMD, in particular, the invasive nature of muscle biop-
sies unless the patient is undergoing elective surgery. In 
addition, we have observed considerable variation in the pro-
liferative and myogenic capability of cells obtained from dys-
trophic muscle, particularly when the tissue shows advanced 
dystrophic pathology. Although myogenic cells from different 
patients with DMD showed some variation in exon skipping 
efficiency in this study, both at the RNA and protein levels, 
exon 8(+9) was generally excluded in more than 50% of the 
transcript products after transfection at the higher concentra-
tions. It is not possible to establish if this variation is because 
of the nature of the mutation (i.e., deletion breakpoints), the 
influence of genetic background on splicing, or limitations of 
in vitro cell culture, such as variations in myogenic capacity.
One alternative to using muscle-derived patient myogenic 
cells is the propagation of dermal fibroblasts and forced 
myogenesis.28 Although the dermal cells can be readily 
obtained with very minor discomfort to the patient, we have 
found that in vitro studies using fibroblasts tend to produce 
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variable results. Although these cells are useful for RNA stud-
ies where typically >30% exon skipping was induced at the 
higher transfection concentrations, analyzing protein in these 
cells is more challenging, presumably reflecting relatively 
inefficient myogenic transformation.
When undertaking western blotting, we attempt to load 
equivalent amounts of normal, untreated and treated patient 
cell extracts to allow estimation of the relative amounts of 
base line and induced dystrophin. Western blot analysis 
showed that untreated myogenic cells from the DMD patients 
produced from 3 to 7% of the levels of dystrophin found in 
normal cells, consistent with reports of exon 3–7 (and 5–7) 
deletions as being “leaky”,9–11 and not strictly conforming to the 
genotype:phenotype correlations.5 Acknowledging the limita-
tions of extrapolating in vitro data, these basal levels of dystro-
phin expression are in line with those expected in muscle from 
an individual with a severe BMD phenotype. Dystrophin levels 
of 3% or less than those in normal muscle are consistent with a 
DMD phenotype. Nicholson et al.29 reported that patients with 
DMD with low, but nevertheless detectable amounts of dystro-
phin became nonambulant some 18 months later than those 
who had no measurable dystrophin. Patients with dystrophin 
levels of 3–7 % of those in normal muscle could be expected 
to show severe BMD or the intermediate form of muscular dys-
trophy, consistent with the phenotypes reported for patients 
with mutations in this region of the dystrophin gene.
The variable basal levels of dystrophin expression in these 
patients could prove problematic when evaluating AOs in clin-
ical studies, unless baseline dystrophin expression is estab-
lished before treatment is initiated. Recent data on extended 
administration of Eteplirsen, an exon 51 splice-switching oli-
gomer, indicates that the duration of treatment may be more 
important in determining the level of dystrophin expression 
than the actual dosage (personal communication). The dose 
escalating study reported by Cirak et al.16 extended over 12 
weeks, and over that time the increases in dystrophin expres-
sion varied from 2–3 fold (i.e., 0.7–2.6% or 5–12.3%) to an 
impressive 9–18 fold (0 to 7–9%, 2 to 18%, and 0.9 to 17%).
It is readily acknowledged that there are enormous differ-
ences between in vivo and in vitro conditions, particularly 
when using an artificial system such as forced myogenesis 
of dermal fibroblasts. However, we were able to induce in 
excess of 10-fold increase in dystrophin expression, in line 
with some of the clinical data,16 and can only speculate if sim-
ilar levels of dystrophin induction over a higher basal level of 
expression in these patients would result in significant func-
tional improvements over time.
The in vitro study reported here cannot conclusively 
account for the origin of the basal dystrophin expression in 
these cells carrying deletions in the minor deletion hotspot. 
Although dystrophin was present in untreated cells, there 
was an unequivocal increase in dystrophin levels after the 
administration of oligomer. Therefore, analysis of basal 
dystrophin expression in DMD muscle, before oligomer 
treatment, should be considered and imperative in clinical 
studies. It remains to be determined if those DMD/severe 
BMD patients with higher basal dystrophin levels will be more 
responsive to oligomer mediated exon skipping. The detect-
able dystrophin protein in muscle from these patients, without 
treatment, reduces the possibility of an immune response to 
the induced dystrophin isoform. We propose H8A(−6+24) to 
be a strong candidate for the treatment of DMD patients with 
deletions of exons 3–7 and 5–7 and further suggest that the 
propensity for these patients to produce “leaky” dystrophin is 
a good reason to expedite exon 8 skipping clinical studies.
Materials and methods
AO design and synthesis. Oligomers consisting of 2OMe 
modified bases on a phosphorothioate backbone were syn-
thesized on an Expedite 8909 synthesizer (Applied Biosys-
tems, Melbourne, Australia), as described by Adams et al.30 
AO sequences are shown in Table 1, with nomenclature 
described by Mann et al.31 Oligomers, identified as efficient 
splice-switching agents, were then synthesized by Gene Tools 
Table 1 AOs used in the study. Synthesized as 2OMe AO, PMO, and PPMOk
AO Target Sequence (5′→3′) Length 2OMe PMO PPMOk
H8A(−10+10) GUA UCA ACA UCU GUA AGC AC 20 Y
H8A(−10+20) UGG AUA GGU GGU AUC AAC AUC UGU AAG CAC 30 Y
H8A(−7+15) GAU AGG UGG UAU CAA CAU CUG U 22 Y
H8A(−7+18) GAU AGG UGG UAU CAA CAU CUG UAA G 25 Y
H8A(−6+14) GGU GGU AUC AAC AUC UGU AA 20 Y
H8A(−6+18) GAU AGG UGG UAU CAA CAU CUG UAA 24 Y Y Y
H8A(−6+24) UAU CUG GAU AGG UGG UAU CAA CAU CUG UAA 30 Y Y Y
H8A(−3+18) GAU AGG UGG UAC CAA CAU CUG U 22 Y
H8A(+42+66) AAA CUU GGA AGA GUG AUG UGA UGU A 25 Y
H8A(+53+83) GCU CAC UUG UUG AGG CAA AAC UUG GAA 27 Y Y Y
H8A(+96+120) GCC UUG GCA ACA UUU CCA CUU CCU G 25 Y
H8A(+134+158) AUG UAA CUG AAA AUG UUC UUC UUU A 25 Y
H8D(+13−12) UAC ACA CUU UAC CUG UUG AGA AUA G 25 Y
2OMe, 2′-O-methyl; AO, antisense oligomers; PMO, phosphorodiamidate morpholino oligomers; PPMOk, PMO conjugated to the cell penetrating peptide K.
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(Philomath, OR) using the PMO chemistry, or AVI Biopharma 
(Bothell, WA) as a PPMOk.32,33
Cell culture and myogenic conversion of fibroblasts. Normal 
human myoblasts were prepared essentially as described by 
Rando et al.34 from de-identified muscle biopsies, obtained 
with informed consent, during elective surgery or following 
diagnostic muscle biopsies. Similarly donated after informed 
consent, de-identified fibroblasts were obtained from skin 
biopsies taken from the patients with DMD (Table 2). The 
use of human tissue has been approved by the University of 
Western Australia Human Ethics Committee (approval num-
ber RA/4/1/2295). Normal myoblasts were proliferated and 
differentiated as described previously by Harding et al.26 All 
cells were plated at 3 × 104 cells/well in 24 well plates that had 
been sequentially pre-treated for 1 hour with 50 μg/ml poly 
D-lysine (Sigma, Sydney, Australia) and 100 μg/ml Matrigel 
(BD Biosciences, Sydney, Australia).
Following fine dissection of the skin biopsies, fibroblasts 
were cultured in Dulbecco’s modified Eagle medium (Invitro-
gen, Melbourne, Australia) supplemented with 20% foetal calf 
serum (Serana, Bunbury, Australia), 1% GlutaMax-I (Gibco, 
Melbourne, Australia), 10 U/ml penicillin (Invitrogen), 10 mg/
ml streptomycin (Invitrogen), and 250 ng/ml amphotericin B 
(Sigma). Fibroblasts were converted to myoblasts through 
forced myogenesis28 by transfection with a MyoD express-
ing adenovirus Ad5.f50.AdApt.MyoD (The Native Antigen 
Company, Oxford, UK), and then differentiated in low serum 
media. Briefly, patient fibroblasts were plated at 3 × 104 cells/
well in 24 well plates that had been sequentially pre-treated 
for 1 hour with 50 μg/ml poly D-lysine (Sigma) and 100 μg/
ml Matrigel (BD Biosciences). Twenty-four hours later, media 
was changed to DMEM supplemented with 5% horse serum 
and the MyoD adenovirus Ad5.f50.AdApt.MyoD at a multi-
plicity of infection of 200. Cells were allowed to differentiate 
for 48 hours after forced myogenesis with the MyoD adenovi-
rus, before being transfected with oligomer.
Transfection of myogenic cells. 2OMeAOs were transfected 
as cationic lipoplexes with Lipofectamine 2000 (1:1 w/w) 
(Invitrogen) in Opti-MEM media (Gibco) as per the manufac-
turer’s instructions.
PMOs were transfected by nucleofection using the Amaxa 
4D-Nucleofector and the Cell Line P3-X kit (Lonza, Basel, 
Switzerland). Cells were trypsinized and counted as described 
above, and 8 × 104 cells per treatment group pelleted at 
600 g and resuspended in 22 μl of solution P3. The PMO was 
added to the cuvette with 20 μl of the cell suspension, which 
was then placed in the Nucleofector and pulsed with pro-
gram CM-132 according to the manufacturer’s instructions. 
Pre-warmed Roswell Park Memorial Institute medium, (80 μl) 
(Invitrogen) was added to each cuvette immediately, and the 
cells were allowed to recover for 10 minutes at 37 °C. The 100 
μl of cell suspension was then transferred to a fresh 1.5 ml 
microfuge tube containing 900 μl of differentiation medium.26 
Each sample was then plated into 2 wells of a 24 well plate 
at 2.5–4 × 104 cells per well, allowing for some loss of cells 
during the nucleofection process and transfers. Nucleofected 
cells were maintained in differentiation media for 2–7 days 
after the treatment before extraction of RNA or protein.
PPMOk solutions were warmed for 5 minutes at 37 °C 
before being diluted in Opti-MEM as indicated, and applied 
directly to the adherent cells at the specified concentrations. 
For each transfection procedure, untreated control samples 
were subjected to the same protocol, except that the splice-
switching oligomer was excluded.
Previous studies have indicated that 48 hours after trans-
fection is sufficient for dystrophin mRNA studies, but 7 days 
incubation allows time for dystrophin to accumulate to lev-
els detectable by western blotting. PPMOk concentrations of 
2 µmol/l were selected for induction of protein, as we have 
previously shown robust exon skipping over the transfection 
range of 300 nmol/l to 10 µmol/l.18
RNA extraction and nested RT-PCR. Total RNA was har vested 
48 hours after transfection from duplicate wells using TRIzol 
(Invitrogen) according to the manufacturer’s instructions, and 
resuspended in 40 μl of sterile water (Baxter Healthcare, 
Sydney, Australia). Amplification conditions were chosen that 
do not excessively enhance sensitivity of transcript detection, 
but allow some correlation between mRNA levels and induced 
dystrophin).35 Approximately 100 ng of total RNA was used 
as template for primary amplification using Superscript III 
One-step RT-PCR system with Platinum Taq (Invitrogen) to 
Table 2 Summary table of DMD mutations and patient cells used in this study. DMD patient muscle-derived cells are identified as DM, and dermal  fibroblasts 
converted to the myogenic lineage by forced myogenesis are shown as DF, western blot carried out (WB)
ID Phenotype Cell type RNA effect Mutation 2OMe PMO PPMOk WB
DM1 DMD Myoblast Δ3–7 (c.94-?_649+?del) Y Y Y
DM2 DMD Myoblast Δ3–7 (c.94-?_649+?del) Y Y Y Y
DM3 DMD Myoblast Δ3–7 (c.94-?_649+?del) Y Y Y
DM4 DMD Myoblast Δ5–7 (c.265-?_649+?del) Y Y Y
DF1 DMD Fibroblast Δ3–7 (c.94-?_649+?del) Y
DF2 DMD Fibroblast Δ3–7 (c.94-?_649+?del) Y
DF3 DMD Fibroblast Δ3–7 (c.94-?_649+?del) Y
DF4 DMD Fibroblast Δ3–7 (c.94-?_649+?del) Y
DF5 DMD Fibroblast Δ3–7 (c.94-?_649+?del) Y
DF6 DMD Fibroblast Δ3–7 (c.94-?_649+?del) Y
2OMe, 2′-O-methyl; DMD, Duchenne muscular dystrophy; PMO, phosphorodiamidate morpholino oligomers; PPMOk, PMO conjugated to the cell penetrating 
peptide K.
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amplify exons 1–10 in samples from the patients with DMD, 
or 3–10 in samples from normal muscle. After 30 cycles 
(myoblasts) or 35 cycles (MyoD converted fibroblasts), a 1 μl 
aliquot was removed and subjected to nested PCR, amplify-
ing exons 1–10 (DMD) or 4–10 (normal), for 30 cycles using 
AmpliTaq Gold (Applied Biosystems). Details of PCR primers 
(Geneworks, Adelaide, Australia) are shown in Table 3.
Gel analysis, imaging, and sequencing. PCR products were 
resolved on 2% agarose gels in TAE buffer and relative 
exon skipping efficiency estimated by densitometry of the 
full length and oligomer-induced PCR products on images 
captured by the Chemi-Smart 3000 system (Vilber Lourmat, 
Marne-la-Vallée, France), as described previously.30 The 
identities of induced transcripts were confirmed by band stab 
isolation,36 purification of templates using UltraClean spin 
columns (MoBio, Carlsbad, CA) and DNA sequencing using 
BigDye V3.1 terminator chemistry (Applied Biosystems) 
as per manufacturer’s instructions. RT-PCR product sizes 
are summarized in Table 4. Sequencing was conducted at 
the Lotterywest State Biomedical Facility Genomics (Perth, 
 Australia). Densitometric analysis was conducted using 
Bio1D-software (Scientific Software Group, Provo, UT).
Western analysis of dystrophin expression. Western blot-
ting was performed using a protocol derived from Cooper 
et al.37 and Nicholson et al.38 Seven days after transfection, 
cells were harvested by scraping, and resuspension in treat-
ment buffer (50 μl/4.5 mg wet pellet weight) consisting of 
125 mmol/l Tris-HCl pH 6.8, 15% sodium dodecyl sulfate, 
10% glycerol, 0.5 mmol/l phenylmethylsulfonyl fluoride, 50 
mmol/l dithiothreitol, bromophenol blue (0.004% w/v), and a 
protease inhibitor cocktail (15 μl/500 μl of treatment buffer) 
(Sigma). Samples were vortexed briefly, sonicated for 1 sec-
ond, 4–8 times at a setting of 30/100 on an ultrasonic proces-
sor (Sonics, Newtown, CT) and heated at 95 °C for 5 minutes. 
Samples were then electrophoresed at 16 °C on a 3–10% 
Tris-Bis/Glycine sodium dodecyl sulfate gradient gel at pH 8.8, 
with a 3% stacking gel, pH 6.8. Fractionated proteins were 
transferred to a FluorotransW PVDF membrane (Pall, Mel-
bourne, Australia) overnight at 18 °C at 290 mA, in a transfer 
buffer without methanol. Dystrophin was detected with NCL-
DYS1 monoclonal anti-dystrophin (Novocastra, Newcastle 
upon Tyne, UK) applied at a dilution of 1:400, and dysferlin 
was detected using NCL-Hamlet1 at a dilution 1:1500 for 2 
hours at room temperature. Detection was performed using 
a Western Breeze kit as per the manufacturer’s instructions 
(Invitrogen). Enhanced chemiluminescence reactions were 
detected directly by the Chemi-Smart 3000 gel documenta-
tion system (Vilber Lourmat), using Chemi-Capt software for 
image acquisition and Bio-1D software (Scientific Software 
Group) for image analysis.
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